Core Viewpoint - Maide Medical (688310.SH) reported a significant increase in revenue and net profit for the fiscal year 2025, indicating a successful operational strategy and market demand for its products [1] Financial Performance - The company achieved an operating revenue of 447 million yuan, representing a year-on-year increase of 62.79% [1] - The net profit attributable to the parent company was 65.26 million yuan, with a net profit of 53.29 million yuan after deducting non-recurring gains and losses, marking a substantial turnaround from previous losses [1] Business Development - The overall revenue growth was driven by the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasized technological innovation and process iteration, which strengthened product competitiveness and market influence [1] - The blood purification and drug-device combination intelligent equipment businesses performed well, particularly due to strong demand growth in the terminal market for medical consumables [1] - The optimistic market outlook for drug-device combination intelligent equipment led the company to focus on new product development and market expansion in this area, resulting in significant revenue growth from these products [1]

Core Viewpoint - The company reported significant growth in revenue and net profit for the fiscal year 2025, indicating a successful execution of its production plans and a strong market demand for its products [1] Financial Performance - The company achieved an operating revenue of 447 million yuan, representing a year-on-year increase of 62.79% [1] - The net profit attributable to the parent company was approximately 65.26 million yuan, with a net profit excluding non-recurring gains and losses of about 53.29 million yuan, marking a substantial turnaround from previous losses [1] Business Development - The overall revenue growth was driven by the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasized technological innovation and process iteration, which strengthened product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment business segments performed well, particularly due to strong demand growth in the terminal market for medical consumables [1] - The optimistic market outlook for medical device combination intelligent equipment led the company to focus on new product development and market expansion in this area, resulting in significant revenue growth from this segment [1]

Core Viewpoint - The company reported significant growth in its 2025 financial performance, achieving a revenue of 447 million yuan, marking a 62.79% increase compared to the previous year, and successfully turning a profit after a substantial loss in the prior period [1] Financial Performance - The company achieved an operating profit of 59.7 million yuan and a total profit of 61.2 million yuan for the year 2025 [1] - The net profit attributable to the parent company reached 65.3 million yuan, with a net profit of 53.3 million yuan after deducting non-recurring gains and losses, indicating a significant turnaround from previous losses [1] Revenue Growth Drivers - The substantial increase in overall revenue is attributed to the orderly implementation of production plans, ensuring effective product delivery [1] - The company emphasized technological innovation and process iteration as dual drivers to enhance product competitiveness and market influence [1] - The blood purification and medical device combination intelligent equipment business segments performed well, particularly due to strong demand growth for medical consumables in the end market [1] - The optimistic market outlook for medical device combination intelligent equipment led the company to focus on new product development and market expansion in this area, resulting in significant revenue growth from this segment [1]

证券代码：688310 证券简称：迈得医疗 公告编号：2026-010 迈得医疗工业设备股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以迈得医疗工业设备股份有限公司（以下简称"公司"）正式披露 的2025年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 44,741.90 | 27,485.08 | 62.79 | | 营业利润 | 5,969.89 | -2,739.63 | 不适用 | | 利润总额 | 6,122.32 | -2,923.18 | 不适用 | | 归属于母公司所有者的净利润 | 6,525.99 | -1,998.12 | 不适用 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | 5,329 ...

Core Insights - The company reported a revenue of 447.42 million yuan for the fiscal year 2025, representing a year-on-year increase of 62.79% [1] - The net profit attributable to the parent company reached 65.26 million yuan, marking a turnaround from previous losses [1] - Total assets at the end of the reporting period amounted to 1.19 billion yuan, reflecting a year-on-year growth of 12.69% [1] - The equity attributable to the parent company's shareholders was 862.40 million yuan, up 6.46% year-on-year [1] - The growth in performance is primarily attributed to the company's coordinated production efforts and commitment to innovation, particularly in the blood purification and medical device combination intelligent equipment sectors, which saw significant revenue increases [1]

Group 1 - The core viewpoint of the news is that Maide Medical (688310) has shown a slight increase in stock price and a mixed performance in financial metrics for the third quarter of 2025, indicating potential growth opportunities despite some challenges in net profit [1][2]. Group 2 - As of February 25, 2026, Maide Medical's stock closed at 17.83 yuan, with a trading volume of 17,200 hands and a total transaction amount of 30.72 million yuan [1]. - The net inflow of main funds was 1.11 million yuan, accounting for 3.6% of the total transaction amount, while retail investors experienced a net outflow of 1.06 million yuan, representing 3.45% of the total transaction amount [1]. - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31%, and a net profit attributable to shareholders of 8.84 million yuan, up 15.82% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 83.64 million yuan, a year-on-year increase of 54.38%, and a net profit of 2.79 million yuan, up 224.07% year-on-year [2]. - The company's debt ratio stands at 29.86%, with a gross profit margin of 40.19% [2].

股票近期走势 经济观察网迈得医疗(688310)近期披露业绩预告，预计2025年净利润扭亏为盈，同时股份回购计划持续 推进，并向控股子公司提供财务资助。 业绩经营情况 公司已发布业绩预告，预计2025年全年归属于母公司所有者的净利润约为6652.13万元，实现扭亏为 盈，营业收入预计约4.47亿元，同比增长62.81%。最终数据将以正式年度报告为准，预计在近期披露。 公司状况 公司于2025年12月30日启动回购计划，拟以2000万至4000万元资金回购股份用于减少注册资本。截至 2026年1月31日，已累计回购0.7803%的股份，回购计划仍在实施期内(有效期至2026年12月30日)。 2026年2月9日，股价单日上涨2.19%，成交额6008.27万元，主力资金净流出486.22万元；融资余额截至 2月2日为6966.36万元，处于近一年较高水平。这些指标反映短期市场关注度。 子公司发展 公司拟向控股子公司浙江迈得顺隐形眼镜有限公司提供不超过1亿元的财务资助，期限3年，该事项已获 董事会审议，后续需关注股东会进展。 以上内容基于公开资料整理，不构成投资建议。 ...

Meeting Overview - The first extraordinary general meeting of shareholders was held on February 9, 2026, at the company's conference room in Yuhuan, Zhejiang Province [2] - The meeting was convened by the board of directors and chaired by Mr. Lin Junhua, the chairman of the board [4] Attendance and Voting - All 8 current directors and the board secretary attended the meeting, along with other senior executives [5] - The voting method combined on-site and online voting, which complied with the Company Law and the company's articles of association [4][3] Resolutions and Voting Results - A key resolution regarding financial assistance to a controlling subsidiary and related party transactions was approved [6] - The voting for this resolution included separate counting for minority investors, and certain related shareholders abstained from voting [7] Legal Compliance - The meeting was witnessed by Shanghai Jintiancheng Law Firm, and the lawyers confirmed that all procedures and resolutions were in compliance with the Company Law and other relevant regulations [8]

Core Viewpoint - The financial performance of Maide Medical (688310) shows a modest increase in revenue and significant growth in net profit for the third quarter of 2025, indicating potential investment opportunities in the medical equipment sector [2]. Financial Performance - For the first three quarters of 2025, Maide Medical reported a main revenue of 225 million yuan, a year-on-year increase of 2.31% [2]. - The net profit attributable to shareholders reached 8.84 million yuan, reflecting a year-on-year increase of 15.82% [2]. - The third quarter of 2025 saw a single-quarter main revenue of 83.64 million yuan, a substantial year-on-year increase of 54.38% [2]. - The single-quarter net profit attributable to shareholders was 2.79 million yuan, marking a significant year-on-year increase of 224.07% [2]. - The company reported a gross margin of 40.19% and a debt ratio of 29.86% [2]. Business Overview - Maide Medical specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment, integrating technology in medical device processes, automation, and software to create unique product and service advantages [2].

上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于迈得医疗工业设备股份有限公司 2026 年第一次临时股东会的 法律意见书 锦 天 域 律 师 事 务 所 ALLBRIGHT LAW OFFICES 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 传真: 021-20511999 电话: 021-20511000 邮编： 200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所（以下简称"本所"）接受迈得医疗工业设备股份 有限公司（以下简称"公司"）的委托，就公司召开 2026 年第一次临时股东会 （以下简称"本次股东会"）的有关事宜，根据《中华人民共和国公司法》（以 下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"） 等相关法律、法规和规范性文件以及《迈得医疗工业设备股份有限公司章程》（以 下简称"《公司章程》"）等内部规章制度的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责 ...